Laser photoradiation therapy of cancer following hematoporphyrin sensitization

Wile, Alan G.; Dahlman, Anton; Burns, Robert; Berns, Michael W.

doi:10.1002/lsm.1900020206

Cited by 56 publications

(14 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current studies utilize a more phototoxic version of hematoporphyrin derivative (HPD), called photofrin I1 (PfII) [4,51. Dihematoporphyrin ethedester (DHE), the photoactive component in PfII (and HPD) [61, is relatively hydrophobic [71.…”

Section: Words: Photodynamic Therapy Cellular Localization Porphyrimentioning

confidence: 99%

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II

1989

Self Cite

View full text Add to dashboard Cite

Primary sites of subcellular destruction with photofrin II (PfII) and mono-L-aspartyl chlorin e6 (MACE) were determined by transmission electron microscopy (TEM). Potorous tridactylus (PTK2) cells were grown in Rose chambers and incubated for 24 hr with a sensitizer concentration sufficient to provide 100% mortality. Cells were irradiated with laser light and fixed and processed for electron microscopy at various times post-irradiation. The results indicate that PfII initially destroys mitochondria, whereas MACE destroys lysosomes. Both conclusions are consistent with fluorescence subcellular localization studies.

show abstract

Section: Words: Photodynamic Therapy Cellular Localization Porphyrimentioning

confidence: 99%

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II

1989

Self Cite

View full text Add to dashboard Cite

show abstract

“…Wile and coworkers [74] described a 75% (complete and partial) response of locally recurrent carcinomas located on various sites in the upper aerodigestive tract. After previous radiotherapy, areas treated with PDT healed well and even repeated applications of this treatment were tolerated well.…”

Section: Introduction and First Clinical Resultsmentioning

confidence: 99%

Photodynamic therapy: a promising new modality for the treatment of cancer

Schuitmaker

Baas

Leengoed

et al. 1996

Journal of Photochemistry and Photobiology B: Biology

274

128

View full text Add to dashboard Cite

The first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as "'a promising new therapy in the treatment of cancer".Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. The sensitizer used in the photodynamic treatment of most patients is Photofrin®, (Photofrin®, the commercial name of dihematoporphyrin ether/ester, containing > 80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2-31 ). It is a complex mixture of porphyrins derived from hematoporphyrin. Although this sensitizer is effective, it is not the most suitable photosensitizer for PDT. Prolonged skin photosensitivity and the relatively low absorbance at 630 rim, a wavelength where tissue penetration of light is not optimal, have been frequently cited as negative aspects hindering general acceptance. A multitude of new sensitizers is currently under evaluation. Most of these "second generation photosensitizers" are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another novel approach is the photosensitization of neoplasms by the induction of endogenous photosensitizers through the application of 5-aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts to indicate developments of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields.

show abstract

“…The details of our current treatment technique have recently been reported [3,10]. Briefly, patients are injected with HPD (Oncology Research and Development, Cheektowaga, NY) at a dose of 3 mg/kg body weight.…”

Section: Materials and Methods Clinical Laser Hpd-prtmentioning

confidence: 99%

Laser photoradiation therapy of cancer: An update of the experience at the university of California, Irvine

et al. 1984

View full text Add to dashboard Cite

This update of the experience at the University of California at Irvine with laser photoradiation therapy (PRT) encompasses the period between May 1981 and June 1983. The results of treatment of 77 patients are reported (head and neck, 39; breast, 33; and lung 5). Head and neck cancer patients received treatment to 114 sites with a complete response (CR) in 28, partial response (PR) in 42, stable disease (SD) in three, and no response (NR) in 34, and an undetermined response in seven. Breast cancer patients were treated in 395 sites with CR in 222, PR in 74, SD in one, NR in 92, and undetermined response in six. The lung cancer patients in this series responded poorly, if at all. In addition to the above patient trials, we have investigated the interaction of laser hematoporphyrin derivative (HPD)-PRT with a chemotherapeutic agent, Cisplatin, against an experimental tumor (RIF-1) in an animal model. We have been unable to demonstrate an additive effect of laser HPD-PRT at total light doses of 25 J/cm2 and 75 J/cm2 with Cisplatin at a dose of 7 mg/kg. However, no additional toxicity was observed in combination therapy, suggesting that sequential application of laser HPD-PRT and Cisplatin may be safely employed in clinical situations. Another area of investigation has been the evaluation of the light-scattering characteristics of a lipid emulsion designed for laser HPD-PRT of bladder tumors. We have demonstrated that it is feasible to gain uniform illumination of the bladder surface with the use of this light-dispersing medium.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Laser photoradiation therapy of cancer following hematoporphyrin sensitization

Cited by 56 publications

References 3 publications

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II

Photodynamic therapy: a promising new modality for the treatment of cancer

Laser photoradiation therapy of cancer: An update of the experience at the university of California, Irvine

Contact Info

Product

Resources

About

Laser photoradiation therapy of cancer following hematoporphyrin sensitization

Cited by 56 publications

References 3 publications

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e6 and photofrin II

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e6 and photofrin II

Photodynamic therapy: a promising new modality for the treatment of cancer

Laser photoradiation therapy of cancer: An update of the experience at the university of California, Irvine

Contact Info

Product

Resources

About

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II

In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e₆ and photofrin II